Experienced team for managed logistics is key
Get updates from the Cell Lines Blog delivered to your inbox.
The promise of MSC therapies to treat deadly manifestations of cytokine storms
Implementation of contingency plans allows for continued progress in therapy development
Why a diverse apheresis center network is critical to business continuity
Are ‘super donors’ the answer to sustainable growth for the allogeneic cell and gene therapy industry?
Why reliance on a small subset of donors could introduce risk for companies
Why established systems and relationships matter
An expert opinion on HLA matching relevance for allogeneic cell therapies
By Jamie Margolis, PhD, Senior Vice President of Donor Services, NMDP/Be The Match